Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2020

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

	Three Months Ended				Nine Months Ended
(In thousands)	March 31,				March 31,
Medical Indication	2020		2019		2020		2019
Analgesic	$	2,811	$	946	$	6,806	$	5,322
Anti-Psychosis		27,858		20,616		78,588		45,541
Cardiovascular		21,746		22,783		67,325		70,233
Central Nervous System		18,566		15,906		57,154		37,565
Endocrinology		—		55,210		—		197,565
Gastrointestinal		20,745		16,501		56,020		47,038
Infectious Disease		21,749		4,162		51,722		13,258
Migraine		12,886		9,846		32,907		32,134
Respiratory/Allergy/Cough/Cold		2,966		2,549		8,747		9,521
Urinary		1,149		2,096		2,817		5,233
Other		8,051		14,247		27,847		37,658
Contract manufacturing revenue		5,845		7,932		17,891		20,498
Total net sales	$	144,372	$	172,794	$	407,824	$	521,566

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2020		2019		2020		2019
Product 1	17	%	11	%	18	%	8	%
Product 2	11	%	—	%	10	%	—	%
Product 3	—	%	32	%	—	%	38	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2020		2019		2020		2019
Customer A	29	%	16	%	25	%	21	%
Customer B	21	%	17	%	24	%	16	%
Customer C	12	%	8	%	11	%	10	%
Customer D	—	%	31	%	—	%	16	%